ArticleFrontiers in endocrinology2026
Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes.
Wei Zhao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.